Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 14Osteosarcoma 9Drug-Related Side Effects and Adverse Reactions 4Gastrointestinal Stromal Tumors 2Uterine Neoplasms 1Neoplasms, Connective and Soft Tissue 1Neoplasm Metastasis 1Liposarcoma 1Head and Neck Neoplasms 1Chordoma 1Chondrosarcoma 1Carcinosarcoma 1Carcinoma 1

Interventions

Specimen Handling 9Paclitaxel 7Magnetic Resonance Spectroscopy 6Carboplatin 6Biopsy 6Nivolumab 5pembrolizumab 3olaparib 3X-Rays 3durvalumab 2ceralasertib 2cediranib 2Taxes 2Immunoglobulin G 2trastuzumab deruxtecan 1sargramostim 1rucaparib 1ribociclib 1rebastinib 1pelcitoclax 1pazopanib 1pamiparib 1liposomal doxorubicin 1cobimetinib 1capivasertib 1cabozantinib 1belinostat 1atezolizumab 1apatinib 1Trabectedin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinosarcoma × apatinib × Sarcoma × Clear all
NCT05265793 2022-03-04

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Fudan University

Phase 2 Unknown
45 enrolled
Sarcoma

Carcinoma, Carcinosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡